{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:21Z","timestamp":1786988121355,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Department of Pharmaceutical Sciences"},{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ejpb.2018.05.029","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T12:46:57Z","timestamp":1527079617000},"page":"80-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Development of stable liquid formulations for oligonucleotides"],"prefix":"10.1016","volume":"129","author":[{"given":"Johanna","family":"Poecheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten A.","family":"Graeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Hoernschemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Storch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Printz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2018.05.029_b0005","doi-asserted-by":"crossref","unstructured":"A. Donner, It is an RNA world, SciBX: Science-Business eXchange, 7, 2014.","DOI":"10.1038\/scibx.2014.815"},{"key":"10.1016\/j.ejpb.2018.05.029_b0010","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1128\/AAC.42.4.971","article-title":"Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922)","volume":"42","author":"Mulamba","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2018.05.029_b0015","doi-asserted-by":"crossref","first-page":"e49006","DOI":"10.1371\/journal.pone.0049006","article-title":"Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy","volume":"7","author":"McGowan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2018.05.029_b0020","article-title":"VEGF inhibition study in ocular neovascularization\u20131 (VISION\u20131): safety evaluation from the pivotal MacugenTM (Pegaptanib Sodium) clinical trials","volume":"45","author":"D'Amico","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2018.05.029_b0025","unstructured":"M. Herper, Approving a muscular dystrophy drug ignites a civil war at the FDA, in: Forbes, 2016."},{"key":"10.1016\/j.ejpb.2018.05.029_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/tnsci-2017-0001","article-title":"ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy","volume":"8","author":"Ottesen","year":"2017","journal-title":"Transl. Neurosci."},{"key":"10.1016\/j.ejpb.2018.05.029_b0035","doi-asserted-by":"crossref","unstructured":"M. Matsui, D.R. Corey, Non-coding RNAs as drug targets, Nat. Rev. Drug Discov., Advance Online Publication (2016).","DOI":"10.1038\/nrd.2016.117"},{"key":"10.1016\/j.ejpb.2018.05.029_b0040","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejpb.2018.05.029_b0045","article-title":"Antisense oligonucleotides: treatment strategies and cellular internalization","volume":"3","author":"Miller","year":"2016","journal-title":"RNA & Disease"},{"key":"10.1016\/j.ejpb.2018.05.029_b0050","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejpb.2018.05.029_b0055","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrg3978","article-title":"Knocking down disease: a progress report on siRNA therapeutics","volume":"16","author":"Wittrup","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejpb.2018.05.029_b0060","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2018.05.029_b0065","article-title":"Aptamers as targeted therapeutics: current potential and challenges","author":"Zhou","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2018.05.029_b0070","doi-asserted-by":"crossref","first-page":"791","DOI":"10.4155\/tde.13.47","article-title":"Oligonucleotide conjugates for therapeutic applications","volume":"4","author":"Winkler","year":"2013","journal-title":"Therapeutic Deliv."},{"key":"10.1016\/j.ejpb.2018.05.029_b0075","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA as a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejpb.2018.05.029_b0080","series-title":"Principles of Nucleic Acid Structure","author":"Egli","year":"2013"},{"key":"10.1016\/j.ejpb.2018.05.029_b0085","article-title":"2\u2032-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity","volume":"5","author":"Wu","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejpb.2018.05.029_b0090","doi-asserted-by":"crossref","unstructured":"J.F. Alterman, L.M. Hall, A.H. Coles, M.R. Hassler, M.-C. Didiot, K. Chase, J. Abraham, E. Sottosanti, E. Johnson, E. Sapp, Hydrophobically modified siRNAs silence Huntingtin mRNA in primary neurons and mouse brain, Mol. Therapy\u2014Nucleic Acids, 4 (2015) e266.","DOI":"10.1038\/mtna.2015.38"},{"key":"10.1016\/j.ejpb.2018.05.029_b0095","unstructured":"S.l. Mart\u00ednez-Montero, G.F. Deleavey, N. Mart\u00edn-Pintado, J.F. Fakhoury, C. Gonz\u00e1lez, M.J. Damha, Locked 2\u2032-deoxy-2\u2032, 4\u2032-difluororibo modified nucleic acids: thermal stability, structural studies, and siRNA activity, ACS Chem. Biol., 10 (2015) 2016\u20132023."},{"key":"10.1016\/j.ejpb.2018.05.029_b0100","doi-asserted-by":"crossref","unstructured":"E. Moroz, S.H. Lee, K. Yamada, F. Halloy, S. Mart\u00ednez-Montero, H. Jahns, J. Hall, M.J. Damha, B. Castagner, J.-C. Leroux, Carrier-free gene silencing by amphiphilic nucleic acid conjugates in differentiated intestinal cells, Mol. Therapy\u2014Nucleic Acids, 5 (2016) e364.","DOI":"10.1038\/mtna.2016.69"},{"key":"10.1016\/j.ejpb.2018.05.029_b0105","doi-asserted-by":"crossref","DOI":"10.1039\/C6OB01960A","article-title":"Synthesis and properties of novel 2\u2032-C, 4\u2032-C-ethyleneoxy-bridged 2\u2032-deoxyribonucleic acids with exocyclic methylene groups","author":"Osawa","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejpb.2018.05.029_b0110","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1089\/nat.2012.0382","article-title":"Locked nucleic acid and aptamers","volume":"22","author":"Karlsen","year":"2012","journal-title":"Nucleic Acid Therapeutics"},{"key":"10.1016\/j.ejpb.2018.05.029_b0115","unstructured":"O.G. Technology, DNA storage and quality, in: 2011."},{"key":"10.1016\/j.ejpb.2018.05.029_b0120","doi-asserted-by":"crossref","unstructured":"J.F. Carpenter, B.S. Chang, W. Garzon-Rodriguez, T.W. Randolph, Rational design of stable lyophilized protein formulations: theory and practice, in: Rational Design of Stable Protein Formulations, Springer, 2002, pp. 109\u2013133.","DOI":"10.1007\/978-1-4615-0557-0_5"},{"key":"10.1016\/j.ejpb.2018.05.029_b0125","doi-asserted-by":"crossref","unstructured":"L.A. Brito, S. Kommareddy, D. Maione, Y. Uematsu, C. Giovani, F. Berlanda Scorza, G.R. Otten, D. Yu, C.W. Mandl, P.W. Mason, P.R. Dormitzer, J.B. Ulmer, A.J. Geall, Chapter seven \u2013 self-amplifying mRNA vaccines, in: D.L. Leaf Huang, W. Ernst (Eds.), Advances in Genetics, Academic Press, 2015, pp. 179\u2013233.","DOI":"10.1016\/bs.adgen.2014.10.005"},{"key":"10.1016\/j.ejpb.2018.05.029_b0130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s10904-012-9694-8","article-title":"Interactions of metal ions with DNA and some applications","volume":"23","author":"Shamsi","year":"2013","journal-title":"J. Inorg. Organomet. Polym Mater."},{"key":"10.1016\/j.ejpb.2018.05.029_b0135","doi-asserted-by":"crossref","unstructured":"H. Tateishi-Karimata, N. Sugimoto, Structure, stability and behaviour of nucleic acids in ionic liquids, Nucleic Acids Res., (2014) gku499.","DOI":"10.1093\/nar\/gku499"},{"key":"10.1016\/j.ejpb.2018.05.029_b0140","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1128\/JVI.13.3.729-739.1974","article-title":"Effect of ultraviolet light on mengovirus: formation of uracil dimers, instability and degradation of capsid, and covalent linkage of protein to viral RNA","volume":"13","author":"Miller","year":"1974","journal-title":"J. Virol."},{"key":"10.1016\/j.ejpb.2018.05.029_b0145","doi-asserted-by":"crossref","first-page":"13371","DOI":"10.1021\/acs.est.6b04281","article-title":"Direct and indirect photochemical reactions in viral RNA measured with RT-qPCR and mass spectrometry","volume":"50","author":"Qiao","year":"2016","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.ejpb.2018.05.029_b0150","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1359-6446(01)01739-1","article-title":"Physical stabilization of DNA-based therapeutics","volume":"6","author":"Anchordoquy","year":"2001","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2018.05.029_b0155","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1021\/cr00102a001","article-title":"Antisense oligonucleotides: a new therapeutic principle","volume":"90","author":"Uhlmann","year":"1990","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejpb.2018.05.029_b0160","series-title":"Pharmaceutical Perspectives of Nucleic Acid-Based Therapy","author":"Mahato","year":"2003"},{"key":"10.1016\/j.ejpb.2018.05.029_b0165","series-title":"Pharmaceutical Aspects of Oligonucleotides","author":"Couvreur","year":"2003"},{"key":"10.1016\/j.ejpb.2018.05.029_b0170","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1093\/nar\/22.23.4997","article-title":"Mechanistic studies on depurination and apurinic site chain breakage in oligodeoxyribonucleotides","volume":"22","author":"Suzuki","year":"1994","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejpb.2018.05.029_b0175","unstructured":"FDA, Sterile Drug Products Produced by Aseptic Processing, Guidance for Industry by Food and Drug Administration \u2013 U.S. Department of Health and Human Services, (2004)."},{"key":"10.1016\/j.ejpb.2018.05.029_b0180","unstructured":"EMA, Draft Guideline on the Sterilization of the Medicinal Product, Active Substance, Excipient and Primary Container, European Agency for the Evaluation of Medicinal Products, (2016)."},{"key":"10.1016\/j.ejpb.2018.05.029_b0185","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ejps.2008.12.003","article-title":"Injectability of biodegradable in situ forming microparticle systems (ISM)","volume":"36","author":"Rungseevijitprapa","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.05.029_b0190","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.copbio.2009.10.006","article-title":"Formulation and manufacturability of biologics","volume":"20","author":"Shire","year":"2009","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ejpb.2018.05.029_b0195","unstructured":"A.B. Gaikwad, DNA Storage Methodologies: Principles and Protocols."},{"key":"10.1016\/j.ejpb.2018.05.029_b0200","doi-asserted-by":"crossref","unstructured":"W.M. Strauss, Preparation of genomic DNA from mammalian tissue, in: Current Protocols in Molecular Biology, John Wiley & Sons, Inc., 2001.","DOI":"10.1002\/0471142727.mb0202s42"},{"key":"10.1016\/j.ejpb.2018.05.029_b0205","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/clinchem\/18.3.206","article-title":"Tris\/Tris\u00b7HCl: a standard buffer for use in the physiologic pH range","volume":"18","author":"Durst","year":"1972","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejpb.2018.05.029_b0210","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-0728(84)80171-0","article-title":"Dissociation constants and related thermodynamic quantities of the protonated acid form of tris-(hydroxymethyl)-aminomethane in mixtures of 2-methoxyethanol and water at different temperatures","volume":"162","author":"El-Harakany","year":"1984","journal-title":"J. Electroanal. Chem. Interfacial Electrochem."},{"key":"10.1016\/j.ejpb.2018.05.029_b0215","first-page":"325","article-title":"Nucleotides and nucleic acids","author":"Nelson","year":"2008","journal-title":"Lehninger Principles Biochem."},{"key":"10.1016\/j.ejpb.2018.05.029_b0220","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/nar\/gki193","article-title":"Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality","volume":"33","author":"Elmen","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejpb.2018.05.029_b0225","doi-asserted-by":"crossref","first-page":"e115950","DOI":"10.1371\/journal.pone.0115950","article-title":"Non-enzymatic depurination of nucleic acids: factors and mechanisms","volume":"9","author":"An","year":"2014","journal-title":"PloS one"},{"key":"10.1016\/j.ejpb.2018.05.029_b0230","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1021\/bi00769a018","article-title":"Rate of depurination of native deoxyribonucleic acid","volume":"11","author":"Lindahl","year":"1972","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejpb.2018.05.029_b0235","unstructured":"IDT, Oligonucleotide Stability Study, in: Integrated DNA Technologies, 2014, pp. Technical Report."},{"key":"10.1016\/j.ejpb.2018.05.029_b0240","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/jps.10140","article-title":"Shear-induced degradation of plasmid DNA","volume":"91","author":"Lengsfeld","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.05.029_b0245","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s004490050552","article-title":"Effect of shear on plasmid DNA in solution","volume":"20","author":"Levy","year":"1999","journal-title":"Bioprocess. Eng."},{"key":"10.1016\/j.ejpb.2018.05.029_b0250","doi-asserted-by":"crossref","unstructured":"C. Lengsfeld, T. Anchordoquy, Basic issues in the manufacture of macromoleucles, in: Handbook of Pharmaceutical Biotechnology, John Wiley & Sons, Inc., 2006, pp. 297\u2013317.","DOI":"10.1002\/9780470117118.ch4a"},{"key":"10.1016\/j.ejpb.2018.05.029_b0255","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ddr.10344","article-title":"Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies","volume":"61","author":"Harris","year":"2004","journal-title":"Drug Devel. Res."},{"key":"10.1016\/j.ejpb.2018.05.029_b0260","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.bpj.2014.02.036","article-title":"Observation of small cluster formation in concentrated monoclonal antibody solutions and its implications to solution viscosity","volume":"106","author":"Yearley","year":"2014","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejpb.2018.05.029_b0265","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/BIR-140649","article-title":"Viscosity measurements of DNA solutions with and without condensing agents","volume":"51","author":"Laesecke","year":"2014","journal-title":"Biorheology"},{"key":"10.1016\/j.ejpb.2018.05.029_b0270","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1021\/mp5000218","article-title":"Specific decrease in solution viscosity of antibodies by arginine for therapeutic formulations","volume":"11","author":"Inoue","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2018.05.029_b0275","first-page":"57","article-title":"Polyamines in living organisms","volume":"1","author":"Yatin","year":"2002","journal-title":"J. Cell Mol. Biol."},{"key":"10.1016\/j.ejpb.2018.05.029_b0280","first-page":"65","article-title":"Excipient selection in parenteral formulation development","volume":"45","author":"Pramanick","year":"2013","journal-title":"Pharma Times"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641117314248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641117314248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T04:50:25Z","timestamp":1604292625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641117314248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":56,"alternative-id":["S0939641117314248"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.05.029","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of stable liquid formulations for oligonucleotides","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.05.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}